Search Results for "Drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug. Results 71 to 80 of 2581 total matches.

Drugs for Assisted Reproduction

   
Treatment Guidelines from The Medical Letter • Oct 01, 2003  (Issue 14)
Drugs for Assisted Reproduction ...
Infertility occurs in about 15% of couples. About one third of infertility is due to problems with ovulation or an anatomic abnormality of the fallopian tube or peritoneum, such as scarring, adhesions or endometriosis. Another third is due to a male infertility factor, most commonly insufficient sperm production or abnormal motility or morphology. The remaining third is unexplained. In older women unexplained infertility is probably caused by diminished quality and quantity of oocytes, decreased implantation and spontaneous pregnancy wastage.
Treat Guidel Med Lett. 2003 Oct;1(14):89-92 |  Show IntroductionHide Introduction

Drug Interactions Correction

   
The Medical Letter on Drugs and Therapeutics • Aug 04, 2003  (Issue 1162)
Drug Interactions Correction ...
In the February 2003 update of the Adverse Drug Interactions Program and in the Handbook of Adverse Drug Interactions 2003, the potentially lethal interaction between selective serotonin reuptake inhibitors (SSRIs) and monoamine oxidase inhibitors (MAOIs) was inadvertently omitted for citalopram (Celexa) and escitalopram (Lexapro). This interaction could occur with any SSRI.
Med Lett Drugs Ther. 2003 Aug 4;45(1162):64 |  Show IntroductionHide Introduction

Table: Some Drug Interactions with Drugs for IBD (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023  (Issue 1680)
Table: Some Drug Interactions with Drugs for IBD (online only) ...
View the Table: Some Drug Interactions with Drugs for IBD
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e114   doi:10.58347/tml.2023.1680c |  Show IntroductionHide Introduction

Drugs Past Their Expiration Date

   
The Medical Letter on Drugs and Therapeutics • Jul 27, 2020  (Issue 1603)
Drugs Past Their Expiration Date ...
Healthcare providers are often asked if drugs can be used past their expiration date. Because of legal restrictions and liability concerns, manufacturers do not sanction such use and usually do not comment on the safety or effectiveness of their products beyond the date on the label. Since our last article on this subject, more data have become available.
Med Lett Drugs Ther. 2020 Jul 27;62(1603):117-9 |  Show IntroductionHide Introduction

Sildenafil: An Oral Drug for Impotence

   
The Medical Letter on Drugs and Therapeutics • May 08, 1998  (Issue 1026)
Sildenafil: An Oral Drug for Impotence ...
Sildenafil citrate (Viagra - Pfizer) is the first oral drug approved by the FDA for treatment of erectile dysfunction. Alprostadil is also marketed for this indication but must be injected into the corpus cavemosum (Caverject) or pushed into the urethra (MUSE).
Med Lett Drugs Ther. 1998 May 8;40(1026):51-2 |  Show IntroductionHide Introduction

Choice of Drug-Eluting Stents

   
The Medical Letter on Drugs and Therapeutics • Dec 24, 2012  (Issue 1406)
Choice of Drug-Eluting Stents ...
The use of intracoronary stents in angioplasty procedures has improved both short- and long-term success rates. In recent years, drug-eluting stents (DESs) have largely replaced bare-metal stents (BMSs).
Med Lett Drugs Ther. 2012 Dec 24;54(1406):102-3 |  Show IntroductionHide Introduction

New Drugs for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Nov 20, 1998  (Issue 1040)
New Drugs for Rheumatoid Arthritis ...
Leflunomide (Arava - Hoechst Marion Roussel), which inhibits pyrimidine synthesis, and etanercept (Enbrel - Immunex/Wyeth-Ayerst), which blocks the action of tumor necrosis factor (TNF), have been approved by the FDA for treatment of rheumatoid arthritis. A third drug, infliximab (Remicade - Centocor), which also blocks TNF and has been used to treat rheumatoid arthritis, was approved earlier for treatment of Crohn's disease. Its use in Crohn's disease will be reviewed in a future issue.
Med Lett Drugs Ther. 1998 Nov 20;40(1040):110-2 |  Show IntroductionHide Introduction

Two New Drugs for Epilepsy

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2000  (Issue 1076)
Two New Drugs for Epilepsy ...
Oxcarbazepine, which is chemically similar to carbamazepine, and levetiracetam, a pyrrolidine acetamide chemically unrelated to other antiepileptic drugs, are the sixth and seventh drugs approved by the US Food and Drug Administration in the last five years for oral use in partial seizures.
Med Lett Drugs Ther. 2000 Apr 17;42(1076):33-5 |  Show IntroductionHide Introduction

Drugs That May Cause Psychiatric Symptoms

   
The Medical Letter on Drugs and Therapeutics • Dec 15, 2008  (Issue 1301)
Drugs That May Cause Psychiatric Symptoms ...
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression.

Click here to view the free full article.
Med Lett Drugs Ther. 2008 Dec 15;50(1301):100-3 |  Show IntroductionHide Introduction

Drugs for Opioid Use Disorder

   
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023  (Issue 1684)
Drugs for Opioid Use Disorder ...
Opioid use disorder is a chronic, relapsing disease with physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections such as HIV and viral hepatitis, adverse pregnancy outcomes, and increased mortality. According to the NIH, there were 80,411 deaths involving an opioid in the US in 2021, more than in any previous year. Several guidelines on the management of opioid use disorder are available; all recommend maintenance pharmacotherapy as the standard of care.
Med Lett Drugs Ther. 2023 Sep 4;65(1684):137-44   doi:10.58347/tml.2023.1684a |  Show IntroductionHide Introduction